image
Healthcare - Biotechnology - NASDAQ - US
$ 37.88
2.07 %
$ 21.3 B
Market Cap
15.15
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Aug, 5, 2025.

The intrinsic value of one RPRX stock under the worst case scenario is HIDDEN Compared to the current market price of 37.9 USD, Royalty Pharma plc is HIDDEN

This DCF valuation model was last updated on Aug, 5, 2025.

The intrinsic value of one RPRX stock under the base case scenario is HIDDEN Compared to the current market price of 37.9 USD, Royalty Pharma plc is HIDDEN

This DCF valuation model was last updated on Aug, 5, 2025.

The intrinsic value of one RPRX stock under the best case scenario is HIDDEN Compared to the current market price of 37.9 USD, Royalty Pharma plc is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart RPRX

image
$38.0$38.0$37.0$37.0$36.0$36.0$35.0$35.0$34.0$34.0$33.0$33.0$32.0$32.0$31.0$31.0$30.0$30.015 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '2515 Jul15 JulAug '25Aug '25
FINANCIALS
2.26 B REVENUE
-3.85%
1.29 B OPERATING INCOME
-13.41%
1.33 B NET INCOME
-21.72%
2.77 B OPERATING CASH FLOW
-7.32%
-2.68 B INVESTING CASH FLOW
-29.20%
361 M FINANCING CASH FLOW
116.81%
568 M REVENUE
-4.34%
534 M OPERATING INCOME
47.56%
433 M NET INCOME
29.63%
596 M OPERATING CASH FLOW
-19.72%
504 M INVESTING CASH FLOW
199.67%
-941 M FINANCING CASH FLOW
-264.90%
Balance Sheet Royalty Pharma plc
image
Current Assets 1.8 B
Cash & Short-Term Investments 987 M
Receivables 27 M
Other Current Assets 788 M
Non-Current Assets 16.4 B
Long-Term Investments 16.4 B
PP&E 0
Other Non-Current Assets 33.5 M
5.42 %4.32 %89.93 %Total Assets$18.2b
Current Liabilities 1.25 B
Accounts Payable 13.4 M
Short-Term Debt 998 M
Other Current Liabilities 242 M
Non-Current Liabilities 6.63 B
Long-Term Debt 6.61 B
Other Non-Current Liabilities 12.1 M
12.66 %3.08 %83.94 %Total Liabilities$7.9b
EFFICIENCY
Earnings Waterfall Royalty Pharma plc
image
Revenue 2.26 B
Cost Of Revenue 0
Gross Profit 2.26 B
Operating Expenses 971 M
Operating Income 1.29 B
Other Expenses -38.8 M
Net Income 1.33 B
3b3b2b2b2b2b1b1b500m500m002b02b(971m)1b39m1bRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
57.07% OPERATING MARGIN
57.07%
37.94% NET MARGIN
37.94%
12.37% ROE
12.37%
4.71% ROA
4.71%
4.64% ROIC
4.64%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Royalty Pharma plc
image
3b3b3b3b2b2b2b2b1b1b500m500m002018201820192019202020202021202120222022202320232024202420252025
Net Income 1.33 B
Depreciation & Amortization 0
Capital Expenditures 0
Stock-Based Compensation 2.34 M
Change in Working Capital 53.4 M
Others 1.44 B
Free Cash Flow 2.77 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Royalty Pharma plc
image
Wall Street analysts predict an average 1-year price target for RPRX of $48.4 , with forecasts ranging from a low of $28 to a high of $54 .
RPRX Lowest Price Target Wall Street Target
28 USD -26.08%
RPRX Average Price Target Wall Street Target
48.4 USD 27.85%
RPRX Highest Price Target Wall Street Target
54 USD 42.56%
Price
Max Price Target
Min Price Target
Average Price Target
55555050454540403535303025252020Sep '24Sep '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
0.71% DIVIDEND YIELD
0.22 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
0.900.900.800.800.700.700.600.600.500.500.400.400.300.300.200.200.100.100.000.000.170.190.20.210.220.170.190.20.210.220.150.170.190.20.210.220.150.640.170.720.190.780.20.820.210.860.22202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership Royalty Pharma plc
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing globally, the future of gene therapy, changes at FDA, and more. youtube.com - 4 days ago
President Trump demands drugmakers slash prices within 60 days CNBC's Joe Kernen reports on the latest news. youtube.com - 4 days ago
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy? Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 6 days ago
Royalty Pharma Declares Third Quarter 2025 Dividend NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share. globenewswire.com - 2 weeks ago
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company's Board of Directors NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Carole Ho and Elizabeth (Bess) Weatherman to its Board of Directors, effective immediately. Carole Ho is Chief Medical Officer and Head of Development at Denali Therapeutics, a biopharmaceutical company focused on neurodegenerative diseases. Bess Weatherman is a Special Limited Partner of Warburg Pincus LLC, a leading global private equity firm focused on growth investing. globenewswire.com - 2 weeks ago
Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025 NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2025 financial results on Wednesday, August 6, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. globenewswire.com - 2 weeks ago
Royalty Pharma: Attractive Acquisition With Upside Risk/Reward On Current Pipeline Royalty Pharma is less exposed to MFN drug pricing risks, offering downside protection in a volatile policy environment. The Revolution Medicines royalty deal provides near-term upside and de-risks pipeline assets, with pivotal data expected in 2026. We forecast 2025 EPS of $4.53 and raise our target price to $45.3, reflecting strong earnings and capital deployment. seekingalpha.com - 1 month ago
Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug Royalty Pharma said on Tuesday will pay up to $2 billion to Revolution Medicines to support the companies' plans for global development and commercialization of the experimental cancer drug daraxonrasib. reuters.com - 1 month ago
Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a $2 billion funding arrangement with Revolution Medicines, consisting of a synthetic royalty of up to $1.25 billion on daraxonrasib and a senior secured loan of up to $750 million. These funds will support Revolution Medicines' plans for global development and commercialization of daraxonrasib and its pipeline programs for patients with RAS-addicted cancers. globenewswire.com - 1 month ago
Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 2:00 p.m. ET. globenewswire.com - 2 months ago
Royalty Pharma Completes the Acquisition of Its External Manager NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC (“RP Management”). The acquisition received overwhelming support from Royalty Pharma's shareholders, with 99.9% of votes cast in favor of the transaction. globenewswire.com - 2 months ago
Royalty Pharma to Present at Upcoming Investor Conferences NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: globenewswire.com - 2 months ago
8. Profile Summary

Royalty Pharma plc RPRX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 21.3 B
Dividend Yield 0.71%
Description Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Contact 110 East 59th Street, New York City, NY, 10022 https://www.royaltypharma.com
IPO Date June 16, 2020
Employees 75
Officers Dr. James Folmar Reddoch Ph.D. Executive Vice President of Investments & Chief Scientific Officer Mr. Eric Cornelius Schneider Senior Vice President & Chief Technology Officer Ms. Kristin Stafford Senior Vice President & Chief Accounting Officer Mr. Ashwin Pai M.D. Executive Vice President of Investments Mr. Christopher Hite Vice Chairman & Executive Vice President Mr. Pablo Gerardo Legorreta Founder, Chairman of the Board & Chief Executive Officer Dr. Marshall Jonathan Urist M.D., Ph.D. Executive Vice President of Research & Investments Mr. Arthur Richard McGivern J.D. Executive Vice President of Investments & General Counsel Mr. Terrance P. Coyne Executive Vice President & Chief Financial Officer Mr. George Wingate Lloyd Executive Vice President of Investments & Chief Legal Officer